Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cell non-autonomous signaling through the conserved C. elegans glycoprotein hormone receptor FSHR-1 regulates cholinergic neurotransmission.
Buckley M, Jacob WP, Bortey L, McClain ME, Ritter AL, Godfrey A, Munneke AS, Ramachandran S, Kenis S, Kolnik JC, Olofsson S, Nenadovich M, Kutoloski T, Rademacher L, Alva A, Heinecke O, Adkins R, Parkar S, Bhagat R, Lunato J, Beets I, Francis MM, Kowalski JR. Buckley M, et al. Among authors: alva a. PLoS Genet. 2024 Nov 19;20(11):e1011461. doi: 10.1371/journal.pgen.1011461. eCollection 2024 Nov. PLoS Genet. 2024. PMID: 39561202 Free PMC article.
Cell non-autonomous signaling through the conserved C. elegans glycopeptide hormone receptor FSHR-1 regulates cholinergic neurotransmission.
Buckley M, Jacob WP, Bortey L, McClain M, Ritter AL, Godfrey A, Munneke AS, Ramachandran S, Kenis S, Kolnik JC, Olofsson S, Adkins R, Kutoloski T, Rademacher L, Heinecke O, Alva A, Beets I, Francis MM, Kowalski JR. Buckley M, et al. Among authors: alva a. bioRxiv [Preprint]. 2024 Feb 12:2024.02.10.578699. doi: 10.1101/2024.02.10.578699. bioRxiv. 2024. Update in: PLoS Genet. 2024 Nov 19;20(11):e1011461. doi: 10.1371/journal.pgen.1011461 PMID: 38405708 Free PMC article. Updated. Preprint.
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, Agarwal N, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, Zakopoulou R, Bamias A, Barrera RM, Marmolejo D, Drakaki A, Pinato DJ, Korolewicz J, Buznego LA, Duran I, Carballeira CC, McKay RR, Stewart TF, Gupta S, Barata P, Yu EY, Koshkin VS, Khaki AR, Grivas P. Talukder R, et al. Among authors: alva a. Clin Genitourin Cancer. 2025 Feb;23(1):102284. doi: 10.1016/j.clgc.2024.102284. Epub 2024 Dec 2. Clin Genitourin Cancer. 2025. PMID: 39798390
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Jindal T, et al. Among authors: alva a. Eur Urol Oncol. 2024 Dec 20:S2588-9311(24)00289-X. doi: 10.1016/j.euo.2024.12.006. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39709257 Free article.
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
Powles T, Csőszi T, Loriot Y, Matsubara N, Geczi L, Cheng SY, Fradet Y, Alva A, Oudard S, Vulsteke C, Morales-Barrera R, Fléchon A, Gunduz S, Liu CC, Moreno BH, Bavle A, Özgüroğlu M. Powles T, et al. Among authors: alva a. Clin Genitourin Cancer. 2025 Feb;23(1):102261. doi: 10.1016/j.clgc.2024.102261. Epub 2024 Nov 1. Clin Genitourin Cancer. 2025. PMID: 39642775 Clinical Trial.
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM Jr; SWOG S1011 Trial Investigators. Lerner SP, et al. Among authors: alva a. N Engl J Med. 2024 Oct 3;391(13):1206-1216. doi: 10.1056/NEJMoa2401497. N Engl J Med. 2024. PMID: 39589370 Free PMC article. Clinical Trial.
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.
Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ, Gafanov R, Joly F, Bedke J, Sella A, Chang YH, Imai K, Moreno BH, Xu JZ, Alva A, Powles T. Mamtani R, et al. Among authors: alva a. Clin Genitourin Cancer. 2025 Feb;23(1):102248. doi: 10.1016/j.clgc.2024.102248. Epub 2024 Oct 28. Clin Genitourin Cancer. 2025. PMID: 39579409 Free article. Clinical Trial.
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N. Fléchon A, et al. Among authors: alva a. Clin Cancer Res. 2024 Dec 2;30(23):5353-5364. doi: 10.1158/1078-0432.CCR-23-3518. Clin Cancer Res. 2024. PMID: 39475359 Free PMC article. Clinical Trial.
251 results